# A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

> **NCT00739453** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 95 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** OSI-906
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00739453
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-23
- **Primary completion:** 2012-03-03
- **Final completion:** 2012-03-03
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00739453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00739453, "A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00739453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*